Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Leveraging Porphysome-Mediated Photodynamic Therapy to Optimize Photochemical Immune Stimulation in Early-Stage Non-Small Cell Lung Cancer
FY 2025-26
Summary
Lung cancer is the leading cause of cancer-related deaths. Although the standard treatment is surgery, many patients are medically inoperable due to severe comorbidities. Photodynamic therapy (PDT) is a minimally invasive technique that uses light-activated drugs to destroy tumours. This treatment provides a promising alternative, significantly improving patients’ quality of life. However, challenges still exist in PDT, particularly for large or hard-to-reach tumours deep within the lung. To address these barriers, our team and collaborators have developed next-generation light-activated nanoparticle drugs, called Porphysomes, along with improved imaging tools to better target lung tumours. Compared to clinically approved PDT, Porphysome-mediated PDT has shown reduced side effects and better patient outcomes, although obtaining complete tumour destruction still proves challenging. Interestingly, following PDT, we have observed that tumours distant from the treated site also shrank. This suggests that PDT carries an indirect, immunological benefit, and this phenomenon was coined photochemical immune stimulation (PCIS). We hypothesize that PCIS could bridge the gaps in PDT to help clear the remaining cancer that PDT fails to destroy. This project will evaluate PCIS efficacy and whether it can sufficiently supplement PDT to overcome the need for complete light-based tumour destruction in deep lung cancers. Using mouse models, we will identify conditions for optimal PCIS, evaluate how strong the immune response is, and test whether it can eliminate remaining cancer when PDT alone cannot. If successful, this work could expand PDT from local treatment to a powerful, immune-based therapy, which will improve long-term tumour control while reducing the risk of cancer relapse.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572886
Name
Dou Esther
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Leveraging Porphysome-Mediated Photodynamic Therapy to Optimize Photochemical Immune Stimulation in Early-Stage Non-Small Cell Lung Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Anti-Tumour Immunity; Immunotherapy; Minimally Invasive Therapeutics; Nanomedicine; Non-Small Cell Lung Cancer (Nsclc); Photochemical Immune Stimulation (Pcis); Photodynamic Therapy (Pdt); Porphysomes; Systemic Immune Response; Tumour Ablation
Abstract
Lung cancer is the leading cause of cancer-related deaths. Although the standard treatment is surgery, many patients are medically inoperable due to severe comorbidities. Photodynamic therapy (PDT) is a minimally invasive technique that uses light-activated drugs to destroy tumours. This treatment provides a promising alternative, significantly improving patients’ quality of life. However, challenges still exist in PDT, particularly for large or hard-to-reach tumours deep within the lung. To address these barriers, our team and collaborators have developed next-generation light-activated nanoparticle drugs, called Porphysomes, along with improved imaging tools to better target lung tumours. Compared to clinically approved PDT, Porphysome-mediated PDT has shown reduced side effects and better patient outcomes, although obtaining complete tumour destruction still proves challenging. Interestingly, following PDT, we have observed that tumours distant from the treated site also shrank. This suggests that PDT carries an indirect, immunological benefit, and this phenomenon was coined photochemical immune stimulation (PCIS). We hypothesize that PCIS could bridge the gaps in PDT to help clear the remaining cancer that PDT fails to destroy. This project will evaluate PCIS efficacy and whether it can sufficiently supplement PDT to overcome the need for complete light-based tumour destruction in deep lung cancers. Using mouse models, we will identify conditions for optimal PCIS, evaluate how strong the immune response is, and test whether it can eliminate remaining cancer when PDT alone cannot. If successful, this work could expand PDT from local treatment to a powerful, immune-based therapy, which will improve long-term tumour control while reducing the risk of cancer relapse.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dou, Esther
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~